Long-term stabilizing of retinal exudation and fluid accumulation contributes to brolucizumab’s efficacy in managing wet age-related macular degeneration (AMD). Visual prognosis could be improved when ...
(RTTNews) - EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last October, expects to report full topline results in the ...
Hosted on MSN1mon
How Is Macular Degeneration Diagnosed?Using OCT, ophthalmologists or optometrists can detect signs of both dry and wet AMD. However, this type of imaging isn’t as effective for differentiating between these types of macular ...
Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm ...
A mid-stage trial of 4D Molecular Therapeutics gene therapy for eye disease age-related macular degeneration ... a cohort of 51 patients with wet or neovascular AMD, a form of the disease where ...
Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...
Age-related macular degeneration may cause a gradual reduction in your central vision over time, so you might not recognize ...
The FDA approved Susvimo for the treatment of diabetic macular edema, according to a press release. The decision was supported by positive 1-year data from the phase 3 Pagoda study, in which Susvimo ...
Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...
EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback